SCHEMBL14090230

SCHEMBL14090230

COc1ncccc1-c1ccc(O)c(-c2nc3ccc(N4CCN(C)CC4)cc3[nH]2)c1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.55
▸ SMN1; SMN2 Q16637 4/20 0.55
▸ TOP1 P11387 3/20 0.55
▸ TOP2A P11388 3/20 0.55
▸ HPGD P15428 1/20 0.55
▸ HSD17B10 Q99714 1/20 0.55
▸ KDM4E B2RXH2 2/20 0.55
▸ NPC1 O15118 1/20 0.55
▸ POLB P06746 1/20 0.55
▸ RAB9A P51151 1/20 0.55
▸ MEN1 O00255 2/20 0.53
▸ MAPT P10636 2/20 0.53
▸ BLM P54132 2/20 0.53
▸ KMT2A Q03164 2/20 0.53
▸ GAA P10253 1/20 0.53
▸ RXFP1 Q9HBX9 1/20 0.53
▸ CDK4 P11802 1/20 0.51
▸ CCNA2 P20248 1/20 0.51
▸ CCND1 P24385 1/20 0.51
▸ CDK2 P24941 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14090376 0.89 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14090239 0.88 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL1509588 0.86 CDK4 (0.47) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL1509531 0.83 ALDH1A1 (0.50) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14090215 0.83 ALDH1A1 (0.62) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL12834289 0.83 LOXL2 (0.41) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL14090255 0.83 ALDH1A1 (0.59) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD
SCHEMBL1509467 0.82 DHFR (0.43) ALDH1A1SMN1; SMN2HSD17B10KDM4ENPC1
SCHEMBL14090417 0.82 NPC1 (0.46) ALDH1A1SMN1; SMN2HPGDNPC1POLB
SCHEMBL14090247 0.82 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2TOP1TOP2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8629147-B2 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2014-01-14 — — US disclosed
US-8629147-B2 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION (US) 2014-01-14 — — US disclosed
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-08-28 — — US disclosed
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders CHEMBRIDGE CORPORATION 2008-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207635-A1 Heterocyclic compounds useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders LCK, MALT1, MYD88 ALDH1A1 2293/4885SMN1; SMN2 3752/4885TOP1 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback